Quarterly ResultAug 12, 2026, 05:13 PM
MariMed Q2 Revenue Up 6% to $41.9M; Net Loss Widens
AI Summary
MariMed Inc. reported record revenue of $41.9 million for the second quarter of 2026, a 6% increase year-over-year. Despite this growth, the company's GAAP net loss widened to $3.6 million from $1.4 million in the prior year quarter, and Non-GAAP Adjusted EBITDA decreased to $3.9 million from $4.8 million. Management highlighted strong sequential growth in both wholesale and retail businesses, with wholesale revenue up 6% and retail revenue up 7% sequentially, and expressed optimism about future growth strategies and potential federal cannabis reform.
Key Highlights
- Q2 2026 revenue increased 6% year-over-year to $41.9 million, marking the highest quarterly revenue in company history.
- GAAP net loss for Q2 2026 was $3.6 million, compared to a net loss of $1.4 million in Q2 2025.
- Non-GAAP Adjusted EBITDA for Q2 2026 was $3.9 million, down from $4.8 million in Q2 2025.
- Wholesale revenue increased 6% sequentially, and retail revenue increased 7% sequentially.
- MariMed's branded products portfolio grew 70 basis points faster than the broader industry in core markets.
- Betty’s Eddies remained the #1-selling edible brand across MariMed’s core states.
- The company generated positive cash flow from operations for the six-month period ended June 30, 2026.
Price Impact
More from MRMD